Navigation Links
Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets
Date:7/14/2009

NEW YORK, July 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson's disease.

Target validation is an essential and historically underresourced phase of drug development in which researchers work to determine whether a molecule or mechanism of interest is a true drug target. While researchers have continued to identify novel targets in recent years through genetic, biochemical and epidemiological studies, a lack of funding for validation studies has long been a major roadblock to the efficient translation of these discoveries into practical therapies that benefit people living with PD.

The Foundation's Target Validation initiative, one of MJFF's Edmond J. Safra Core Programs for PD Research, provides intellectual and financial resources to help push potential PD drug targets one step closer to clinical trials and Parkinson's patients.

Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.

As with all MJFF grants, full funding is dependent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

The transcription factor Nrf2 as a target to reduce neurodegeneration and neuroinflammation in Parkinson's disease

Antonio Cuadrado, PhD, Universidad Autonoma de Madrid, Spain

Neuroprotection by P
'/>"/>

SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Randomized Study Presented at ACOG 2009 Annual Meeting Confirming ... cohosh has been widely used in Europe and also ... flashes, night sweats, occasional irritability and mood swings. While ... question of liver safety has arisen in a few ...
... REDWOOD CITY, Calif., May 5 AcelRx Pharmaceuticals, ... Phase 2 clinical trial of its ARX-01 Sufentanil ... candidate being developed for management of acute post-operative ... objective of this open-label study is to assess ...
Cached Medicine Technology:No Causality Found Between Black Cohosh and Liver Problems 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 2AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System 3
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
(Date:4/23/2014)... has long been considered to be between 180 and ... used refined microscopic techniques that indicate a much smaller ... tract is only as large as a normal studio ... which passes from the mouth through the esophagus and ... 5 meters in a normal adult, and is built ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... Getting to the bottom of Alzheimer,s disease has ... turns and controversies. In the latest crook in ... insight into the interaction between proteins associated with ... journal ACS Chemical Neuroscience , could have ... K. Surewicz, Krzysztof Nieznanski and colleagues explain that ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2
... one of the biggest controversies in fetal surgery and ... medicine physicians// around the world: What's the best way ... most common conditions requiring fetal surgery and the leading ... NIH-funded study on TTTS, conducted at 17 centers in ...
... a gift that brought tears to the receiver and to ... dollars was pledged to the staff at Toronto’s Hospital for Sick ... scion of a beer baron and well-established friend of the hospital. ... Management mutual fund company and his wife Sonia, have pledged this ...
... A child of seven years has succumbed to the flu, in British ... as it usually peaks in the months of December and January. ... say experts. ,According to Dr. Theresa Tam of the Public ... because of influenza and in a bad year that can go up ...
... fewer infection and death rates is announced by the NHS ... tried out successfully in United States. This announcement was received ... ,The incentive scheme initially is set for heart treatments, ... case of very sick patients and severe complications, the hospitals ...
... Cancer is a complex and common disease caused by ... ,Recent research shows that the constitutional mutation in PALB2 ... ,Previous studies have shown that genes are responsible ... of breast cancer. The two major familial breast cancer ...
... Using a unique weaving machine of their design, Duke ... "scaffold" that could greatly improve the ability of physicians ... cells. ,"If further experiments are successful, ... three or four years," said Franklin Moutos, a graduate ...
Cached Medicine News:Health News:Timeliness, a Critical Factor in Treating TTTS 2Health News:Timeliness, a Critical Factor in Treating TTTS 3Health News:Record Donation to Children’s Hospita 2Health News:Flu Strikes Late - Child Succumbs 2Health News:Mutation In PALB2 Elevates Risk of Cancer 2Health News:Woven Cartilage 2
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
...
Medicine Products: